PAXMEDICA INC (PXMD) Stock Price & Overview

NASDAQ:PXMD • US70424C2035

Current stock price

0.6883 USD
-0.06 (-7.61%)
At close:
0.37 USD
-0.32 (-46.24%)
After Hours:

The current stock price of PXMD is 0.6883 USD. Today PXMD is down by -7.61%. In the past month the price increased by 27.7%. In the past year, price decreased by -97.28%.

PXMD Key Statistics

52-Week Range0.372 - 29.75
Current PXMD stock price positioned within its 52-week range.
1-Month Range0.4011 - 1.19
Current PXMD stock price positioned within its 1-month range.
Market Cap
5.1M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-15.85
Dividend Yield
N/A

PXMD Stock Performance

Today
-7.61%
1 Week
-0.53%
1 Month
+27.70%
3 Months
+43.40%
Longer-term
6 Months -73.53%
1 Year -97.28%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

PXMD Stock Chart

PAXMEDICA INC / PXMD Daily stock chart

PXMD Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to PXMD. When comparing the yearly performance of all stocks, PXMD is a bad performer in the overall market: 88.21% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PXMD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PXMD. The financial health of PXMD is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PXMD Earnings

Next Earnings DateMay 13, 2024
Last Earnings DateMar 11, 2024
PeriodQ4 / 2023
EPS Reported-$1.45
Revenue Reported
EPS Surprise -61.54%
Revenue Surprise %

PXMD Forecast & Estimates

null analysts have analysed PXMD and the average price target is 3.06 USD. This implies a price increase of 344.57% is expected in the next year compared to the current price of 0.6883.


Analysts
AnalystsN/A
Price Target3.06 (344.57%)
EPS Next Y88.34%
Revenue Next YearN/A

PXMD Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

PXMD Financial Highlights

Over the last trailing twelve months PXMD reported a non-GAAP Earnings per Share(EPS) of -15.85. The EPS increased by 23.95% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-18.29M
Industry RankSector Rank
PM (TTM) N/A
ROA -321.98%
ROE -540.3%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%79.11%
Sales Q2Q%N/A
EPS 1Y (TTM)23.95%
Revenue 1Y (TTM)N/A

PXMD Ownership

Ownership
Inst Owners0%
Shares7.41M
Float6.81M
Ins Owners100.3%
Short Float %0.01%
Short Ratio0

About PXMD

Company Profile

PXMD logo image PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Company Info

IPO: 2022-08-19

PAXMEDICA INC

303 South Broadway, Suite 125

Tarrytown NEW YORK US

Employees: 3

PXMD Company Website

Phone: 19149872876

PAXMEDICA INC / PXMD FAQ

What does PAXMEDICA INC do?

PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.


Can you provide the latest stock price for PAXMEDICA INC?

The current stock price of PXMD is 0.6883 USD. The price decreased by -7.61% in the last trading session.


Does PXMD stock pay dividends?

PXMD does not pay a dividend.


How is the ChartMill rating for PAXMEDICA INC?

PXMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is PAXMEDICA INC (PXMD) stock traded?

PXMD stock is listed on the Nasdaq exchange.


What is the GICS sector and industry of PXMD stock?

PAXMEDICA INC (PXMD) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the market cap for PAXMEDICA INC?

PAXMEDICA INC (PXMD) has a market capitalization of 5.10M USD. This makes PXMD a Nano Cap stock.